The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
=== Recreational drug === GBL is a prodrug of GHB (naturally produced) and its recreational use comes entirely as a result of this. GBL overdose can cause intoxication, severe sickness, coma and death. To bypass GHB restriction laws, home synthesis kits were introduced to transform GBL and/or 1,4-B into GHB.
==== Liberation of Czechoslovakia ==== On 8 May 1944, Beneš signed an agreement with Soviet leaders stipulating that "Czechoslovak territory liberated by Soviet armies" would be placed under Czechoslovak civilian control. On 21 September, Czechoslovak troops formed in the Soviet-liberated village, Kalinov, which was the first liberated settlement of Slovakia, located near the Dukla Pass in northeastern part of the country. Slovakia and the Czech lands were occupied mostly by Soviet troops (the Red Army), supported by Czech and Slovak resistance, from the east to the west; only southwestern Bohemia was liberated by other Allied troops from the west. Even at the end of the war, German troops massacred Czech civilians; the Massacre in Trhová Kamenice and the Massacre at Javoříčko are examples of this. A provisional Czechoslovak government was established by the Soviets in the eastern Slovak city of Košice on 4 April 1945. "National committees" (supervised by the Red Army) took over the administration of towns as the Germans were expelled. Bratislava was taken by the Soviets on 4 April. On April 18th, 1945, elements of the U.S. 90th Infantry Division of General George S. Patton’s U.S. 3rd Army crossed the western border of the former Czechoslovakia border near the town of Cheb, effectively cutting Germany in half. Elements of the 3rd Army would probe the Czech border for the rest of April, moving parallel down the border in an advance towards Linz, Austria.
In flue-gas desulfurization, exhaust gases from fossil-fuel power stations and other processes (e.g. cement manufacture) are scrubbed to reduce their sulfur dioxide content, by injecting finely ground limestone: SO2 + 0.5 O2 + CaCO3 → CaSO4 + CO2 Related sulfur-trapping methods use lime and some produces an impure calcium sulfite, which oxidizes on storage to calcium sulfate.
Sources: en.wikipedia.org
Diff-Quik is a commercial Romanowsky stain variant used to rapidly stain and differentiate a variety of pathology specimens. It is most frequently used for blood films and cytopathological smears, including fine needle aspirates. The Diff-Quik procedure is based on a modification of the Wright-Giemsa stain pioneered by Harleco in the 1970s, and has advantages over the routine Wright-Giemsa staining technique in that it reduces the 4-minute process into a much shorter operation and allows for selective increased eosinophilic or basophilic staining depending upon the time the smear is left in the staining solutions. There are generic brands of such stain, and the trade name is sometimes used loosely to refer to any such stain (much as "Coke" or "Band-Aid" are sometimes used imprecisely).
Diagenesis () is the process of physical and chemical changes in sediments first caused by water-rock interactions, microbial activity, and compaction after their deposition. Increased pressure and temperature only start to play a role as sediments become buried much deeper in the Earth's crust. In the early stages, the transformation of poorly consolidated sediments into sedimentary rock (lithification) is simply accompanied by a reduction in porosity and water expulsion (clay sediments), while their main mineralogical assemblages remain unaltered. As the rock is carried deeper by further deposition above, its organic content is progressively transformed into kerogens and bitumens. The process of diagenesis excludes surface alteration (weathering) and deep metamorphism. There is no sharp boundary between diagenesis and metamorphism, but the latter occurs at higher temperatures and pressures. Hydrothermal solutions, meteoric groundwater, rock porosity, permeability, dissolution/precipitation reactions, and time are all influential factors. After deposition, sediments are compacted as they are buried beneath successive layers of sediment and cemented by minerals that precipitate from solution. Grains of sediment, rock fragments and fossils can be replaced by other minerals (e.g. calcite, siderite, pyrite or marcasite) during diagenesis. Porosity usually decreases during diagenesis, except in rare cases such as dissolution of minerals and dolomitization.
The benefit of ACE inhibitors extends even to those who have to commence dialysis to treat their kidney disease, and may give sufficient benefit to allow the discontinuation of renal replacement therapy.
Sources: en.wikipedia.org
Additionally, in the cardiovascular field, the COL4A1 and COL4A2 regions on chromosome 13q34 are a highly replicated locus for coronary artery disease. In a normal wall of arteries, collagen type IV acts to inhibit smooth muscle cell proliferation. Accordingly, it was demonstrated that protein expression of collagen type IV in human vascular smooth muscle cells is regulated by both SMAD3 protein and TGFβ mediated stimulation of mRNA. Altogether, it was concluded that the pathogenesis of coronary artery disease may be regulated by COL4A1 and COL4A2 genes.
Thrombotic thrombocytopenic purpura - uncommon and potentially fatal thrombotic microangiopathy characterized by severe thrombocytopenia, organ ischemia connected to diffuse microvascular platelet rich-thrombi, and microangiopathic hemolytic anemia. Relapsing polychondritis - uncommon multisystem autoimmune disease with an unclear etiology that is marked by progressive cartilaginous tissue loss and recurring episodes of inflammation. Mixed connective tissue disease - systemic autoimmune disease that shares characteristics with two or more other systemic autoimmune diseases, such as rheumatoid arthritis, polymyositis/dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. It is an example of overlap syndrome. Undifferentiated connective tissue disease - unclassifiable systemic autoimmune disorders that do not meet any of the current classification requirements for connective tissue diseases, yet have clinical and serological signs similar to connective tissue diseases. Psoriatic arthritis - inflammatory musculoskeletal condition linked to psoriasis. Cryoglobulinemia - condition sometimes associated with systemic lupus erythematosus or rheumatoid arthritis in which there are abnormal proteins in the blood. IgG4-related disease - chronic inflammatory condition in which there is deposition of connective tissue (fibrosis) in different organs. Potentially life-threatening. Periaortitis - a group of rare vascular inflammatory diseases in which fibrous inflammatory tissue develops around the aorta or other structures such as the ureters.
(Cm, Z=96): Curium-247, 1.64 × 107 years / 1.56 × 107 years (Am, Z=95): Americium-243; 7,370 years (Bk, Z=97): Berkelium-247; 1.4 × 103 years / 1380 years (Cf, Z=98): Californium-251; 898 years (Es, Z=99): Einsteinium-252; 471.7 days (Fm, Z=100): Fermium-257; 100.5 days (Md, Z=101): Mendelevium-258; 51.5 days (Lr, Z=103): Lawrencium-262; 3.6 hours = 216 minutes (No, Z=102): Nobelium-259; 58 minutes (Rf, Z=104): Rutherfordium-263; approximately 10 minutes (Sg, Z=106): Seaborgium-269; 5 ± 2 minutes (Bh, Z=107): Bohrium-270; approximately 61 seconds
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.